Canaccord Genuity restated their buy rating on shares of Exact Sciences Corporation (NASDAQ:EXAS) in a research report released on Wednesday morning, Marketbeat Ratings reports. The brokerage currently has a $45.00 target price on the medical research company’s stock, up from their prior target price of $42.00.

EXAS has been the topic of several other reports. Vetr raised shares of Exact Sciences Corporation from a sell rating to a hold rating and set a $36.55 target price on the stock in a report on Tuesday, July 25th. Lake Street Capital raised their target price on shares of Exact Sciences Corporation from $30.00 to $41.00 and gave the company a hold rating in a report on Wednesday. Roth Capital raised their target price on shares of Exact Sciences Corporation from $40.00 to $46.00 and gave the company a buy rating in a report on Wednesday. Cowen and Company raised their target price on shares of Exact Sciences Corporation from $40.00 to $45.00 and gave the company an outperform rating in a report on Friday, May 5th. Finally, BTIG Research reissued a buy rating and issued a $45.00 target price (up from $35.00) on shares of Exact Sciences Corporation in a report on Monday, July 17th. Five equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Exact Sciences Corporation presently has an average rating of Buy and a consensus price target of $40.37.

Shares of Exact Sciences Corporation (EXAS) traded up 4.06% during mid-day trading on Wednesday, reaching $39.47. 1,969,011 shares of the company’s stock traded hands. The stock’s market cap is $4.70 billion. The firm has a 50 day moving average price of $36.19 and a 200-day moving average price of $27.48. Exact Sciences Corporation has a 12 month low of $13.05 and a 12 month high of $42.18.

Exact Sciences Corporation (NASDAQ:EXAS) last issued its quarterly earnings data on Tuesday, July 25th. The medical research company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.10. Exact Sciences Corporation had a negative net margin of 83.08% and a negative return on equity of 36.36%. The business had revenue of $57.65 million during the quarter, compared to analysts’ expectations of $47.73 million. On average, analysts predict that Exact Sciences Corporation will post ($1.18) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was first published by Watch List News and is the sole property of of Watch List News. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/exact-sciences-corporation-nasdaqexas-receives-buy-rating-from-canaccord-genuity/1462645.html.

In related news, SVP D Scott Coward sold 1,987 shares of Exact Sciences Corporation stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $35.21, for a total transaction of $69,962.27. Following the sale, the senior vice president now directly owns 57,603 shares of the company’s stock, valued at approximately $2,028,201.63. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 4.00% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its stake in shares of Exact Sciences Corporation by 6.4% in the first quarter. Vanguard Group Inc. now owns 8,759,628 shares of the medical research company’s stock valued at $206,903,000 after buying an additional 528,352 shares during the period. BlackRock Inc. raised its stake in shares of Exact Sciences Corporation by 45,816.0% in the first quarter. BlackRock Inc. now owns 6,804,297 shares of the medical research company’s stock valued at $160,718,000 after buying an additional 6,789,478 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Exact Sciences Corporation by 98.1% in the first quarter. JPMorgan Chase & Co. now owns 4,985,657 shares of the medical research company’s stock valued at $117,761,000 after buying an additional 2,468,376 shares during the period. OppenheimerFunds Inc. raised its stake in shares of Exact Sciences Corporation by 66.8% in the first quarter. OppenheimerFunds Inc. now owns 2,502,398 shares of the medical research company’s stock valued at $59,107,000 after buying an additional 1,002,398 shares during the period. Finally, Point72 Asset Management L.P. raised its stake in shares of Exact Sciences Corporation by 1,534.3% in the first quarter. Point72 Asset Management L.P. now owns 2,500,476 shares of the medical research company’s stock valued at $59,061,000 after buying an additional 2,347,476 shares during the period. 85.07% of the stock is currently owned by institutional investors.

About Exact Sciences Corporation

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Analyst Recommendations for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.